RNA-Based Therapeutic Mechanisms of Action
RNA-based therapeutics utilize distinct mechanisms of action to target various biological pathways, offering innovative solutions for a range of diseases. RNA drugs such as antisense oligonucleotides (ASOs ), small interfering RNA (siRNA), messenger RNA (mRNA) therapies, including mRNA vaccines and gene editing (CRISPR) enable precise modulation of gene expression. By harnessing the established design rules of RNA, combined with sequence and chemical optimization and delivery vehicles, researchers can quickly design drug candidates, paving the way for breakthroughs in conditions such as genetic disorders, cancers, and infectious diseases.
ASO-based therapeutics (antisense oligonucleotides)
Antisense oligonucleotides (ASOs) are short, synthetic strands of chemically modified nucleic acids designed to bind to specific RNA molecules. They can have a number of different mechanisms of action (MOA), such as downregulating harmful genes, modulating the splicing of pre-mRNA, and promoting the expression of silenced genes. Leverage our end-to-end services, from selecting MOA to IND studies and regulatory filing support.
Strategic Guidance for ASO Development
Considered screening, efficacy and toxicity strategies can significantly accelerate and optimize ASO development timelines. Our on-demand webinar explains how a holistic approach supports an efficient path to get your therapy to patients quickly.
Watch On Demand
siRNA-based therapeutics (small interfering RNA)
Small interfering RNA (siRNA) is a class of double-stranded RNA molecules, typically about 20-25 base pairs in length and chemically modified, that activate the RNA interference (RNAi) pathway. siRNA specifically targets the selected messenger RNA (mRNA) for degradation, thereby preventing the production of specific proteins. This mechanism is widely utilized in research and forms the basis of marketed drugs for several diseases.
mRNA encoded CAR-Ts (messenger RNA)
CAR-T RNA therapeutics approach involves the genetic modification of a patient's T cells, which are critical components of the immune system. By utilizing messenger RNA (mRNA), researchers can effectively instruct these T cells to express chimeric antigen receptors (CARs) that are specifically designed to recognize and target cancer cells and potentially other indications.
RNA Vaccines
RNA vaccines, in particular the COVID-19 vaccines, have revolutionized the approach to preventing viral infections by prompting the immune system to respond effectively against specific pathogens. Unlike traditional vaccines, which often rely on weakened or inactivated forms of viruses, RNA vaccines use messenger RNA (mRNA) to instruct cells to produce a harmless piece of the virus’s spike protein. This prompts the immune system to recognize and combat the virus if exposed in the future.
mRNA-encoded antibodies
Leveraging mRNA nanomedicine approaches to express biologics circumvents many manufacturing challenges and relies on in vivo production of antibodies within a patient, improving both the cost of sophisticated antibodies and time to clinic.
Recent work demonstrates that therapeutic antibodies translated in vivo from mRNA can be readily detected within hours following infusion into preclinical models and persist for several days or weeks. Peak levels of circulating mRNA-encoded antibodies are comparable to infused recombinant equivalents dosed to patients and are within favorable therapeutic ranges in recent Phase I trials.
Frequently Asked Questions (FAQs) About RNA-based Therapeutics
-
What challenges do researchers face when developing RNA-based therapeutics for diseases?
Researchers face several challenges when developing RNA-based treatments for diseases:
- Understanding the mechanism of action: the exact ways RNA therapies interact with biological pathways can be complex, and understanding these processes is crucial for optimizing treatments.
- Stability: mRNA molecules are inherently unstable and can degrade quickly in biological environments. Formulating mRNA in a way that allows it to remain stable until it reaches its target is a significant hurdle. Oligonucleotide-based therapies are chemically modified to provide the required stability
- Delivery: It is crucial to efficiently deliver mRNA to the right cells or tissues. Many methods, such as lipid nanoparticles oligo-conjugates, improve the specificity of delivery to particular organs.
- Immunogenicity: RNA can provoke an immune response, which may lead to inflammation or other adverse effects. Researchers need to minimize these responses while ensuring the treatment is effective.
- Manufacturing: Producing RNA-based therapeutics at scale for clinical use poses logistical and technical challenges, including cost and quality control.
- Regulatory hurdles: Like all candidate drugs, RNA-based therapies must undergo rigorous safety testing to conform to the regulatory processes.
Overcoming these challenges will be vital for successfully developing and commercializing RNA-based therapies for various diseases.
-
How do you determine which RNA-based therapeutic is most effective for a specific disease?
We can help determine which RNA-based therapeutic is most suitable for your specific disease through several key steps:
- Reviewing Genetic Testing and Biomarkers: Some RNA therapies are designed to target specific genetic mutations or biomarkers associated with a disease. Genetic testing can inform patients about their unique biological profile, which guides therapy selection.
- Understand the Mechanism of Action: Different RNA therapeutics, such as siRNA, mRNA, or ASOs , have different mechanisms. A thorough understanding of the disease biology can help identify the most appropriate option.
- Evaluating Treatment Goals and Alternatives: Patients should consider their specific treatment goals (e.g., symptom relief, disease modification).
- Testing Safety and Efficacy: Understanding the safety profile of a specific RNA therapeutic, including possible side effects, is crucial in making an informed decision.